Glutamate as a therapeutic target in psychiatric disorders - PubMed (original) (raw)
Review
. 2004 Nov;9(11):984-97, 979.
doi: 10.1038/sj.mp.4001551.
Affiliations
- PMID: 15278097
- DOI: 10.1038/sj.mp.4001551
Review
Glutamate as a therapeutic target in psychiatric disorders
D C Javitt. Mol Psychiatry. 2004 Nov.
Abstract
Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic neurotransmission may be modulated at multiple levels, only a minority of which are currently being exploited for pharmaceutical development. Ionotropic receptors for glutamate are divided into N-methyl-D-aspartate receptor (NMDAR) and AMPA receptor subtypes. NMDAR have been implicated in the pathophysiology of schizophrenia. The glycine modulatory site of the NMDAR is currently a favored therapeutic target, with several modulatory agents currently undergoing clinical development. Of these, the full agonists glycine and D-serine have both shown to induce significant, large effect size reductions in persistent negative and cognitive symptoms when added to traditional or newer atypical antipsychotics in double-blind, placebo-controlled clinical studies. Glycine (GLYT1) and small neutral amino-acid (SNAT) transporters, which regulate glycine levels, represent additional targets for drug development, and may represent a site of action of clozapine. Brain transporters for D-serine have recently been described. Metabotropic glutamate receptors are positively (Group I) or negatively (Groups II and III) coupled to glutamatergic neurotransmission. Metabotropic modulators are currently under preclinical development for neuropsychiatric conditions, including schizophrenia, depression and anxiety disorders. Other conditions for which glutamate modulators may prove effective include stroke, epilepsy, Alzheimer disease and PTSD.
Similar articles
- Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U. Heresco-Levy U. Expert Opin Emerg Drugs. 2005 Nov;10(4):827-44. doi: 10.1517/14728214.10.4.827. Expert Opin Emerg Drugs. 2005. PMID: 16262565 Review. - Glycine modulators in schizophrenia.
Javitt DC. Javitt DC. Curr Opin Investig Drugs. 2002 Jul;3(7):1067-72. Curr Opin Investig Drugs. 2002. PMID: 12186269 Review. - The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS, Lipton SA. Chen HS, et al. J Neurochem. 2006 Jun;97(6):1611-26. doi: 10.1111/j.1471-4159.2006.03991.x. J Neurochem. 2006. PMID: 16805772 Review. - Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
Heresco-Levy U. Heresco-Levy U. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1113-23. doi: 10.1016/j.pnpbp.2003.09.007. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 14642971 Review. - Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC. Javitt DC. Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5. Int Rev Neurobiol. 2007. PMID: 17349858 Review.
Cited by
- Transcriptomic pathology of neocortical microcircuit cell types across psychiatric disorders.
Arbabi K, Newton DF, Oh H, Davie MC, Lewis DA, Wainberg M, Tripathy SJ, Sibille E. Arbabi K, et al. Mol Psychiatry. 2024 Sep 5. doi: 10.1038/s41380-024-02707-1. Online ahead of print. Mol Psychiatry. 2024. PMID: 39237723 - A Comprehensive Review of Schizophrenia and Antipsychotic Metabolism as a Predictor of Treatment Response.
Pham M, Caglayan A. Pham M, et al. Cureus. 2024 Jul 24;16(7):e65279. doi: 10.7759/cureus.65279. eCollection 2024 Jul. Cureus. 2024. PMID: 39184784 Free PMC article. Review. - Faster bi-stable visual switching in psychosis.
Killebrew KW, Moser HR, Grant AN, Marjańska M, Sponheim SR, Schallmo MP. Killebrew KW, et al. Transl Psychiatry. 2024 May 7;14(1):201. doi: 10.1038/s41398-024-02913-z. Transl Psychiatry. 2024. PMID: 38714650 Free PMC article. - Glutamate production from aerial nitrogen using the nitrogen-fixing bacterium Klebsiella oxytoca.
Yoshidome D, Hidaka M, Miyanaga T, Ito Y, Kosono S, Nishiyama M. Yoshidome D, et al. Commun Biol. 2024 Apr 11;7(1):443. doi: 10.1038/s42003-024-06147-z. Commun Biol. 2024. PMID: 38605181 Free PMC article. - Glycine and clozapine: potential relevance for the treatment of Parkinson's disease.
Maddaford S, Huot P. Maddaford S, et al. Neurodegener Dis Manag. 2024;14(3-4):47-49. doi: 10.2217/nmt-2024-0005. Epub 2024 Apr 11. Neurodegener Dis Manag. 2024. PMID: 38602420 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical